Photo de l'auteur
8 oeuvres 598 utilisateurs 13 critiques 1 Favoris

A propos de l'auteur

Barry Werth is the author of "The Billion-Dollar Molecule" & "Damages". He has written about Newton Arvin for "The New Yorker" & has also been published in "GQ" & "The New York Times Magazine". He lives in Northampton, Massachusetts. (Bowker Author Biography)

Comprend les noms: Barry Werth

Crédit image: Gerald R. Ford Library and Museum Director Elaine Didier, left, at the Ford Library and Museum on April 20-21, 2006 with Barry Werth[1] Credit: Courtesy Gerald R. Ford Museum. Rights Information: Public Domain (No usage fees, no permission required).

Œuvres de Barry Werth

Étiqueté

Partage des connaissances

Date de naissance
1952-08-22
Sexe
male

Membres

Critiques

Way too much nitty gritty detail for a lay reader. If you were involved in this company or a scientist you might enjoy it more than I did.
 
Signalé
BrendaRT20 | 2 autres critiques | Sep 3, 2023 |
Great follow up to his first book, The Billion Dollar Molecule. For me origin stories are more fascinating than the "maintenance" story. This book "feels" right with respect to the topic - its frantic prose matches the pace of science - many fits and starts - especially for a company that's 1. invested in beating out the competition with a tighter budget, 2. maturing to a proper drug producing pharmaceutical business. The investigative reporting is extremely thorough and if you're not into the science or business, it'll fail to appeal to you. For me it was too much on the financial side of things - constant monitoring of stock prices - I would have to have a better grasp of the business side to appreciate it. I liked the last part, which was quite revealing and transparent about the drug approval process from the trenches.… (plus d'informations)
 
Signalé
bsmashers | 1 autre critique | Aug 1, 2020 |
Werth's book about a company's inception and its revolutionary use of rational drug design should be required reading for all in the sciences. It highlights to amazing extents the pros and cons of academia and industry, and as a current PhD student, I can fully relate to the issues. The scientific struggles of publishing and politics are all excruciatingly detailed, and you're left in awe of the immense strength and will of the characters. Werth's prose is riveting as well. I wish there were a more recent book of equal calibre, detailing maybe a company's trials in genomic medicine.… (plus d'informations)
 
Signalé
bsmashers | 2 autres critiques | Aug 1, 2020 |
A very interesting story of a pharmaceutical startup. So much hype, with no solid basis, and yet they survive. Werth does a good job explaining the business, the science, and the experience of doing the science.

> Scientists, unlike, say, athletes, conjure their own competition. They seldom know precisely whom they’re competing with or where they are in the race. They hear things—rumors, reports—but the information comes at a distance and with a price: It may be exaggerated, deliberately misleading, or simply false. The atmosphere in a lab in the throes of a heated project is insular, secretive, xenophobic, superheated, and paranoid.

> "There's two situations where you want to be aggressive about publishing. One is when you're behind; the other is when you're ahead. When you're ahead, you demoralize the other guy. When you're behind, you have nothing to lose. It's when you don't know that you want to be most careful."
… (plus d'informations)
 
Signalé
breic | 2 autres critiques | Aug 2, 2019 |

Listes

Prix et récompenses

Vous aimerez peut-être aussi

Statistiques

Œuvres
8
Membres
598
Popularité
#42,016
Évaluation
3.9
Critiques
13
ISBN
31
Langues
2
Favoris
1

Tableaux et graphiques